Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is an iodinated contrast agent presented as an injection solution for intravenous use. It provides radiographic contrast enhancement for diagnostic imaging procedures, helping visualize vascular structures and organ systems in patients undergoing radiology examinations. It is commonly employed in angiographic, computed tomography, urographic, and myelographic studies.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, diagnostic imaging centres, and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Optiray (ioversol) is employed in radiographic imaging procedures that require iodine‑based contrast enhancement.

- Angiography: enhances visualization of blood vessels for diagnostic and interventional procedures. - Computed tomography (CT) scans: improves delineation of anatomical structures and lesion detection. - Intravenous urography: provides contrast for detailed imaging of the urinary tract. - Myelography: supplies contrast to outline the spinal canal and nerve roots.

Ioversol may be associated with a range of adverse reactions, ranging from mild to severe.

Common Side Effects: - Warmth or flushing at the injection site. - Metallic or bitter taste in the mouth. - Nausea or vomiting shortly after injection. - Mild headache that resolves spontaneously. - Transient hypotension during or after administration. - Injection site pain or erythema.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Acute renal impairment or contrast‑induced nephropathy. - Seizures or convulsions in rare cases. - Cardiac arrhythmias or myocardial depression. - Pulmonary edema or respiratory distress. - Severe hypotension or shock unresponsive to treatment.

When using Optiray, several precautions should be observed to minimize risk. - Assess renal function: evaluate serum creatinine and eGFR before administration. - Review allergy history: confirm no prior severe reaction to iodinated contrast. - Use lowest effective dose: tailor volume to patient size and imaging requirement. - Monitor vital signs: observe blood pressure and heart rate during injection. - Avoid in patients with known iodine hypersensitivity: consider alternative imaging methods. - Hydrate patient: ensure adequate fluid intake before and after the procedure. - Store at ambient temperature: keep in original container, protect from light and moisture.

Optiray can interact with certain medications and substances, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use of other iodinated contrast agents: cumulative iodine exposure may exacerbate toxicity. - Co‑administration with nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) in patients with renal impairment: heightened risk of contrast‑induced nephropathy. - Use with metformin in patients with reduced renal function: may precipitate lactic acidosis; discontinue metformin as recommended.

Moderate Interactions (Monitor Closely): - Concomitant diuretics: may alter renal excretion of ioversol, requiring hydration monitoring. - Thyroid hormone therapy: excess iodine can affect thyroid hormone levels and test results. - Anticoagulants: increased bleeding risk during invasive imaging; monitor coagulation parameters.